Written by Gabriella Tedone The Third National Italian Meeting of A.I.G. (Associazione Italiana GIST) was held at Fondazione IRCCS Istituto Nazionale dei Tumori (INT), in Milan on Saturday, February 27, 2010. For the 99 patients and [...]
The LRG research team continues to investigate a number of key areas. These include research into ways to overcome drug resistance, improve initial response to treatment, clinical trial support, high throughput screening and establishing the [...]
By Belinda Ehrlich, LRG Program Associate & Erin Kristoff, Newsletter Editor And the winner is... After careful consideration, the Life Raft Group has chosen the recipient of the GIST Clinician of the Year award – Dr. [...]
Researchers and staff from the Life Raft Group and representatives from Mexico’s science and medical community came together to commit to their mission of improving the survival of gastrointestinal stromal tumor (GIST) patients in Latin [...]
Nobel Prize winner Harold E. Varmus, M.D., took the oath of office to become the National Cancer Institute’s (NCI) 14th director in July 2010. NCI is one of the 27 Institutes and Centers that comprise the [...]
Written by Stacey McAully My name is Stacey and most of you will have seen us in the April edition of the newsletter. I have always known I have wanted to do something to raise money [...]
The following excerpt has been reprinted from an article in the Contactgroep GIST newsletter,“Van GISTeren naar morgen” with permission. Norman Scherzer, the American who founded the Life Raft Group ten years ago, stayed with his [...]
A new target has been found for wild-type and pediatric GIST. GISTs without mutations in either of the two genes commonly mutated in GIST typically respond poorly to Gleevec. Andrew Godwin, Ph.D. of Fox Chase Cancer [...]
The Manse on Marsh Street was the location of the first GIST gathering on January 10, 2010 in San Luis Obispo, California. Chris Skiff owner/developer of The Manse on Marsh Street, an up scale [...]
When Morty Wagman underwent surgery to remove a gastrointestinal stromal tumour (GIST) in 2008 with his wife Judi by his side, he was faced with a concerning 55 percent chance that his cancer would return. Then, his oncologist told him about Gleevec (imatinib), a treatment that could greatly reduce the risk of his cancer returning, and Wagman felt empowered and hopeful. Today, he and his wife applaud Health Canada for approving Gleevec for patients with this potentially life-threatening condition, at an earlier stage in the disease.
